Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease characterized by fibrostenosing disease ~~**independent of small bowel involvement**~~, said method comprising:

~~**determining the presence or absence in an individual**~~ (a) genotyping an individual for the presence or absence of ~~**a fibrostenosis-predisposing**~~ the SNP 13 allele in the NOD2/CARD15 gene using enzymatic amplification of nucleic acid from said individual, wherein said ~~**fibrostenosis-predisposing**~~ SNP 13 allele is an insertion of a G at position 248 of SEQ ID NO:5 or an insertion of a C at position 294 of SEQ ID NO:6; and ~~**(SNP 13),**~~

~~**wherein**~~ (b) indicating that the presence of said ~~**fibrostenosis-predisposing**~~ SNP 13 allele is diagnostic of or predictive of susceptibility to the clinical subtype of Crohn's disease characterized by fibrostenosing disease ~~**independent of small bowel involvement**~~.

2. (Canceled)

3. (Canceled)

4. (Currently amended) The method of claim 1, wherein NF-kappa B activation by a NOD2/CARD15 polypeptide encoded by said ~~**fibrostenosis-predisposing**~~ SNP 13 allele is reduced as compared to NF-kappa B activation by a wild-type NOD2/CARD15 polypeptide.

5. (Canceled)

6. (Canceled)

7. (Canceled)

8. (Canceled)

9. (Canceled)

10. (Canceled)

11. (Canceled)

12. (Canceled)

13. (Canceled)

14. (Canceled)

15. (Canceled)

16. (Currently amended) The method of claim 1, wherein said ~~fibrostenosis-predisposing~~ SNP 13 allele is associated with said clinical subtype of Crohn's disease characterized by fibrostenosing disease ~~independent of small bowel involvement~~ with an odds ratio of at least 2 and a lower 95% confidence limit greater than 1.

17. (Currently amended) The method of claim 1, further comprising generating a report indicating the presence or absence in said individual of said ~~fibrostenosis-predisposing~~ SNP 13 allele.

18. (Currently amended) The method of claim 1, further comprising generating a report indicating the presence or absence in said individual of said clinical subtype of Crohn's disease characterized by fibrostenosing disease ~~independent of small bowel involvement~~.

19. (Canceled)

20. (Currently amended) The method of claim **[[19]] 1**, wherein said amplification is polymerase chain reaction amplification.

21. (Original) The method of claim 20, wherein said polymerase chain reaction amplification is performed using one or more fluorescently labeled probes.

22. (Previously presented) The method of claim 20, wherein said polymerase chain reaction amplification is performed using one or more probes comprising a DNA minor groove binder.

23. (Currently amended) A method of optimizing therapy in an individual, said method comprising:

(a) ~~determining the presence or absence in said individual~~ genotyping an individual for the presence or absence of ~~a fibrostenosis-predisposing~~ the SNP 13 allele in the NOD2/CARD15 gene using enzymatic amplification of nucleic acid from said individual, wherein said ~~fibrostenosis-predisposing~~ SNP 13 allele is an insertion of a G at position 248 of SEQ ID NO:5 or an insertion of a C at position 294 of SEQ ID NO:6; ~~(SNP 13),~~

(b) diagnosing individuals in which said ~~fibrostenosis-predisposing~~ SNP 13 allele is present as having a fibrostenosing subtype of Crohn's disease; [[,]] and

(c) treating said individual having a fibrostenosing subtype of Crohn's disease based on said diagnosis.

24. (Currently amended) The method of claim 23, wherein said ~~fibrostenosis-predisposing~~ SNP 13 allele is associated with said clinical subtype of Crohn's disease characterized by fibrostenosing disease ~~independent of small bowel involvement~~ with an odds ratio of at least 2 and a lower 95% confidence limit greater than 1.

25. (Currently amended) The method of claim 23, further comprising generating a report indicating the presence or absence in said individual of said ~~fibrostenosis-predisposing~~ SNP 13 allele.

26. (Currently amended) The method of claim 23, further comprising generating a report indicating the presence or absence in said individual of said clinical subtype of Crohn's disease characterized by fibrostenosing disease ~~independent of small bowel involvement~~.

27. (Canceled)

28. (Currently amended) The method of claim **[[27]]** **23**, wherein said amplification is polymerase chain reaction amplification.

29. (Previously presented) The method of claim 28, wherein said polymerase chain reaction amplification is performed using one or more fluorescently labeled probes.

30. (Previously presented) The method of claim 28, wherein said polymerase chain reaction amplification is performed using one or more probes comprising a DNA minor groove binder.